祥生医疗(688358) - 2022 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2022 was ¥125,824,572.92, representing a year-on-year increase of 23.49%[5] - Net profit attributable to shareholders for the same period was ¥49,864,043.16, up 62.99% year-on-year[5] - The net profit after deducting non-recurring gains and losses reached ¥49,233,278.27, reflecting a 68.22% increase compared to the previous year[5] - Basic and diluted earnings per share were both ¥0.45, an increase of 66.67% compared to the same period last year[6] - The net profit attributable to shareholders for the year-to-date period was ¥125,599,972.62, up 61.49% year-on-year[5] - Net profit for the third quarter of 2022 was ¥125,599,972.62, compared to ¥77,775,013.19 in the same quarter of 2021, reflecting an increase of approximately 61.5%[22] - Basic and diluted earnings per share for the third quarter of 2022 were both ¥1.12, up from ¥0.69 in the same quarter of 2021, marking a growth of about 62.3%[23] Cash Flow - The cash flow generated from operating activities was ¥16,415,556.55, showing a significant increase of 869.81% year-on-year[6] - Cash inflow from operating activities for the first three quarters of 2022 totaled ¥368,785,244.45, compared to ¥308,432,725.95 in 2021, representing an increase of approximately 19.6%[24] - The net cash flow from operating activities was $28,769,350.89, a significant increase from $3,554,235.75 in the previous year, reflecting a strong operational performance[25] - The total cash outflow from operating activities was $340,015,893.56, an increase from $304,878,490.20 year-over-year, reflecting higher operational costs[25] Assets and Liabilities - The company's total assets at the end of the reporting period were ¥1,519,940,604.82, an increase of 8.72% from the end of the previous year[6] - As of September 30, 2022, the total assets of Wuxi Xiangsheng Medical Technology Co., Ltd. amounted to CNY 1,519,940,604.82, an increase from CNY 1,398,069,571.61 at the end of 2021, reflecting a growth of approximately 8.7%[16] - The total liabilities as of the end of the third quarter of 2022 were ¥183,050,920.88, an increase from ¥152,488,030.11 at the end of the previous year, reflecting a growth of approximately 20.1%[21] - Total current liabilities increased to CNY 175,167,467.17 from CNY 139,726,642.35, which is an increase of about 25.4%[17] - The company reported a total non-current asset value of CNY 158,521,522.35, up from CNY 127,756,854.19, reflecting a growth of approximately 24.1%[17] Research and Development - Research and development expenses totaled ¥23,618,053.04, accounting for 18.77% of operating revenue, which is an increase of 0.09 percentage points year-on-year[6] - Research and development expenses for the third quarter of 2022 amounted to ¥62,010,190.82, up from ¥49,822,013.70 in the same quarter of 2021, indicating a growth of about 24.4%[21] Shareholder Information - The company reported a total of 6,437 common shareholders at the end of the reporting period[12] - The total equity attributable to shareholders reached ¥1,336,889,683.94, compared to ¥1,245,581,541.50 in the previous year, indicating an increase of about 7.3%[21] Dividend and Investment Activities - The company paid $40,000,000.00 in dividends during the quarter, a decrease from $64,000,000.00 in the same period last year, reflecting a change in dividend policy[25] - The total cash inflow from investment activities was $1,621,226,645.21, compared to $2,220,758,253.10 in the same quarter last year, indicating a decrease in investment returns[25] - The net cash flow from investment activities was $251,719,545.52, down from $528,654,789.97 year-over-year, suggesting a decline in investment profitability[25] - The cash outflow for investment activities was $1,369,507,099.69, compared to $1,692,103,463.13 in the previous year, indicating a reduction in capital expenditures[25] Tax and Deferred Income - The company reported a tax expense of ¥14,185,566.51 for the third quarter of 2022, compared to ¥6,421,552.97 in the same quarter of 2021, which is an increase of approximately 120.5%[22] - Deferred income as of the end of the third quarter of 2022 was ¥2,108,248.15, down from ¥3,542,468.62 in the previous year, indicating a decrease of about 40.5%[21] Market and Future Outlook - The company has not disclosed any new product launches or technological advancements in the provided reports[15] - There are no indications of market expansion or mergers and acquisitions mentioned in the current financial reports[15] - The report does not provide specific future outlook or performance guidance for the upcoming quarters[15]